Skip to content
Unrated Drug recall · FDA · Published May 18, 2023

Aurolife Glycopyrrolate Tablets Recall: Impurities Risk Serious Harm

Aurolife Pharma recalls 1 mg Glycopyrrolate tablets due to failed impurities tests. These prescription drugs may contain harmful substances. Consumers should contact the manufacturer for details.

🇺🇸 FDA recall #D-0877-2023DrugAurolife ›
Take action

Contact the company

Recalling firmAurolife Pharma, LLC2400 US Highway 130 · Dayton, NJ 08810-1519
✎ GovInfoNow plain-language explainer

Aurolife Pharma is recalling 100-count bottles of 1 mg Glycopyrrolate tablets (Rx only) because they failed impurities and degradation tests. This could mean the tablets contain harmful substances that might cause serious health issues if taken. Read more at govinfonow.com/recall/33436-aurolife-glycopyrrolate-tablets-recall-impurities-risk-serious-harm.

Source Summary by GovInfoNow · govinfonow.com/recall/33436-aurolife-glycopyrrolate-tablets-recall-impurities-risk-serious-harm · Updated August 17, 2026 · FDA enforcement record: FDA #D-0877-2023

Cite this page

“Aurolife Glycopyrrolate Tablets Recall: Impurities Risk Serious Harm.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33436-aurolife-glycopyrrolate-tablets-recall-impurities-risk-serious-harm. Based on FDA recall #D-0877-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0877-2023%22&limit=1).

The FDA announced on May 18, 2023, that Aurolife Pharma, LLC is recalling Glycopyrrolate Tablets, USP, 1 mg, due to failed impurities and degradation specifications. The Class III recall affects distributed bottles from Aurobindo Pharma USA, Inc.

How to tell if you have it

  • Brand: Aurolife
  • Product: Glycopyrrolate Tablets, USP, 1 mg, 100-count bottles
  • NDC: 13107-014-01
  • Lot #: 01421038A1
  • Exp. Date: 05/2023

The hazard

The recall is due to failed impurities and degradation specifications in the tablets, according to the FDA.

Context

GovInfoNow's records show Aurolife Pharma, LLC has issued three other recalls since August 23, 2019. Other recent recalls of similar products include Novadoz Glycopyrrolate Oral Solution Recall (December 15, 2025), Precision Dose Glycopyrrolate Oral Solution Recall (July 14, 2026), and Ajanta Pharma Fluphenazine Tablets Recall (August 25, 2026).

How to tell if you have this one

Check for 100-count bottles labeled 'Glycopyrrolate Tablets, USP, 1 mg' with NDC 13107-014-01 and lot number 01421038A1. These were distributed by Aurobindo Pharma USA, Inc. in East Windsor, NJ.

  • Brand
    Aurolife
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the NDC code 13107-014-01 and lot number 01421038A1 on the bottle.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 15 months after the firm started it.

1. Firm started the recall: May 18, 202312. FDA classified it Class III: Jun 20, 202323. Published in FDA’s Enforcement Report: Jun 28, 202334. FDA terminated the recall: Aug 28, 2024420232024
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this product safe to use?

The recall indicates potential harm, but the exact risk level is unknown. Do not use if you have the specific lot number.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0877-2023 (May 18, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0877-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA